Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, retrospective study comparing risk of hypoglycemia with Toujeo with other basal insulins in type 2 diabetes patients

Trial Profile

An observational, retrospective study comparing risk of hypoglycemia with Toujeo with other basal insulins in type 2 diabetes patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2018

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DELIVER 2
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Apr 2017 New trial record
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 02 Apr 2017 Results presented at the Endocrine Society 2017 Annual Meeting (ENDO 2017), according to a Sanofi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top